Immix Biopharma Overview
Latest ROE for Immix Biopharma: -17.44% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-17.44%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immix Biopharma (IMMX) currently reports a ROE of -17.44%. That is below the sector sector average of -5.93%. Use the charts on this page to explore Immix Biopharma's ROE history and peer comparisons.
Immix Biopharma's ROE of -17.44% is lower than the its sector sector average of -5.93%. That is roughly 193.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immix Biopharma's current -17.44% should be judged against industry norms (sector average: -5.93%) and against IMMX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -17.44%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.93%. From there, open related valuation or income-statement pages for Immix Biopharma, and consider following IMMX for alerts when major investors trade the stock.
